Stay updated on Nivolumab Ibrutinib in CLL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Ibrutinib in CLL Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Revision tag updated from v3.5.3 to v3.5.4, indicating the page now reflects the latest revision. This change represents an update to the page version rather than any study data or content.
    Difference
    0.0%
    Check dated 2026-05-15T15:19:11.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page’s footer/site revision tag was updated from **v3.5.2** to **v3.5.3**, indicating a general system release rather than a change to the clinical trial record.
    Difference
    0.0%
    Check dated 2026-04-24T06:33:29.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:50:32.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Added 'B-cell chronic lymphocytic leukemia' to the study's Conditions section.
    Difference
    0.0%
    Check dated 2026-04-02T15:43:23.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Page revision updated to v3.5.0, replacing the previous v3.4.3 revision.
    Difference
    0.0%
    Check dated 2026-03-19T06:40:58.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T02:21:02.000Z thumbnail image

Stay in the know with updates to Nivolumab Ibrutinib in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.